CJC no DAC.
CJC-1295 without DAC (Drug Affinity Complex), also known as Modified GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). With the molecular formula C₁₅₂H₂₅₂N₄₄O₄₂ and a molec...
Lab Verified
Clinical Grade
PMID Cited
Mechanism of Action.
Published preclinical research has characterized the following molecular pathways and receptor interactions for CJC no DAC.
GHRH Receptor
CJC-1295 NO DAC binds to GHRH receptors on pituitary somatotrophs, activating adenylate cyclase and increasing intracellular cAMP in cell culture.
Growth Hormone Release
The peptide triggers intracellular calcium release and growth hormone secretion through GHRH receptor activation.
Clinical Literature
Research review on CJC no DAC molecular characterization.
Preclinical studies have characterized the molecular properties and receptor binding profiles of CJC no DAC in standardized assay systems.
CJC no DAC structure-activity relationship analysis.
Structure-activity relationship studies have examined the functional domains and binding characteristics of CJC no DAC in cell-free and cell-based systems.
RESEARCH USE ONLY: This compound is intended exclusively for in vitro laboratory research. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Not evaluated by the FDA. Must be 21+ to purchase.
Related Compounds.
GH SecretagoguesCJC/IPA
$62.00Blend · Mixed
For in vitro research use only. Not for human consumption.
GH SecretagoguesFOXO4
$196.00C228H388N86O64 · 5358.06 g/mol
For in vitro research use only. Not for human consumption.
GH SecretagoguesIpamorelin
$28.00C38H49N9O5 · 711.87 g/mol
For in vitro research use only. Not for human consumption.